CervoMed has strengthened its balance sheet through a private placement while advancing multiple neurological disease programs.

CervoMed (NASDAQ: CRVO) announced a private placement expected to generate approximately $10.5 million in upfront gross proceeds.

The financing is expected to extend the company's operational runway through the second quarter of 2027, providing additional flexibility as it advances development programs.

Management continues to pursue a strategic partnership for the Phase 3 development of neflamapimod in dementia with Lewy bodies. Investors are also awaiting upcoming Phase 2a biomarker data and additional milestones related to the company's ALS research initiatives.

The capital raise provides greater visibility into near-term funding needs while supporting ongoing clinical development efforts.